Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19

J Card Fail. 2020 Oct;26(10):895-897. doi: 10.1016/j.cardfail.2020.09.011. Epub 2020 Sep 19.

Authors

Irina Sobol¹, Melana Yuzefpolskaya², Zachary Roth², Paolo C Colombo², Evelyn Horn³, Koji Takeda⁴, Gabriel Sayer², Nir Uriel², Yoshifumi Naka⁴

Affiliations

¹ Department of Medicine, Division of Cardiology, Weill Cornell Medicine, New York, New York. Electronic address: irs9009@med.cornell.edu.
² Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
³ Department of Medicine, Division of Cardiology, Weill Cornell Medicine, New York, New York.
⁴ Department of Surgery, Division of Cardiothoracic and Vascular Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.

No abstract available

MeSH terms

Adult
Aged
Anticoagulants / therapeutic use
Betacoronavirus*
COVID-19
Coronavirus Infections / therapy*
Diabetes Mellitus
Female
Ferritins / blood
Fibrin Fibrinogen Degradation Products / analysis
Glucocorticoids / therapeutic use
Heart Failure / therapy
Heart-Assist Devices*
Hospitalization
Humans
Hydroxychloroquine / therapeutic use
Hypertension
Intubation, Intratracheal
Kidney Failure, Chronic
Lymphopenia
Male
Middle Aged
Obesity
Oxygen Inhalation Therapy
Pandemics
Pneumonia, Viral / therapy*
Retrospective Studies
SARS-CoV-2
Troponin / blood

Substances

Anticoagulants
Fibrin Fibrinogen Degradation Products
Glucocorticoids
Troponin
fibrin fragment D
Hydroxychloroquine
Ferritins